Renaissance Technologies
ELDN icon

Renaissance Technologies’s Eledon Pharmaceuticals ELDN Stock Holding History

Renaissance Technologies’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.8K Sell
24,600
-152,390
-86% -$359K ﹤0.01% 3066
2025
Q4 		$267K Sell
176,990
-172,210
-49% -$409K ﹤0.01% 2804
2025
Q3 		$904K Buy
349,200
+158,527
+83% +$463K ﹤0.01% 2536
2025
Q2 		$517K Buy
190,673
+67,900
+55% +$204K ﹤0.01% 2813
2025
Q1 		$416K Sell
122,773
-24,400
-17% -$100K ﹤0.01% 2815
2024
Q4 		$606K Buy
147,173
+11,300
+8% +$44.5K ﹤0.01% 2758
2024
Q3 		$338K Sell
135,873
-900
-0.7% -$2.41K ﹤0.01% 2938
2024
Q2 		$361K Buy
136,773
+49,704
+57% +$119K ﹤0.01% 2839
2024
Q1 		$179K Buy
87,069
+17,896
+26% +$31.9K ﹤0.01% 3249
2023
Q4 		$125K Buy
69,173
+7,200
+12% +$10K ﹤0.01% 3246
2023
Q3 		$85K Buy
61,973
+1,600
+3% +$2.13K ﹤0.01% 3279
2023
Q2 		$83K Buy
60,373
+28,200
+88% +$58.8K ﹤0.01% 3513
2023
Q1 		$76K Buy
32,173
+2,500
+8% +$6.7K ﹤0.01% 3568
2022
Q4 		$68K Sell
29,673
-2,200
-7% -$5.44K ﹤0.01% 3728
2022
Q3 		$88K Sell
31,873
-300
-0.9% -$955 ﹤0.01% 3633
2022
Q2 		$79K Buy
32,173
+13,700
+74% +$41.8K ﹤0.01% 3902
2022
Q1 		$73K Buy
18,473
+4,800
+35% +$18.6K ﹤0.01% 3846
2021
Q4 		$60K Sell
13,673
-25,990
-66% -$131K ﹤0.01% 3763
2021
Q3 		$245K Buy
39,663
+18,556
+88% +$130K ﹤0.01% 3137
2021
Q2 		$167K Sell
21,107
-5,944
-22% -$56.1K ﹤0.01% 3281
2021
Q1 		$289K Sell
27,051
-16,200
-37% -$244K ﹤0.01% 3066
2020
Q4 		$666K Buy
43,251
+1,132
+3% +$21.6K ﹤0.01% 2698
2020
Q3 		$720K Buy
42,119
+6,826
+19% +$67.2K ﹤0.01% 2674
2020
Q2 		$291K Buy
35,293
+9,886
+39% +$112K ﹤0.01% 3053
2020
Q1 		$178K Buy
25,407
+88
+0.3% +$841 ﹤0.01% 3120
2019
Q4 		$264K Buy
25,319
+4,084
+19% +$43.3K ﹤0.01% 3099
2019
Q3 		$237K Sell
21,235
-1,513
-7% -$21.8K ﹤0.01% 3096
2019
Q2 		$414K Buy
22,748
+11,531
+103% +$505K ﹤0.01% 3068
2019
Q1 		$812K Sell
11,217
-1,772
-14% -$118K ﹤0.01% 2760
2018
Q4 		$374K Sell
12,989
-986
-7% -$62.9K ﹤0.01% 2956
2018
Q3 		$1.18M Buy
13,975
+3,109
+29% +$317K ﹤0.01% 2536
2018
Q2 		$1.37M Buy
10,866
+4,762
+78% +$492K ﹤0.01% 2462
2018
Q1 		$554K Buy
6,104
+922
+18% +$67.9K ﹤0.01% 2876
2017
Q4 		$379K Buy
5,182
+522
+11% +$39.4K ﹤0.01% 2952
2017
Q3 		$437K Buy
4,660
+1,172
+34% +$97.3K ﹤0.01% 2826
2017
Q2 		$367K Buy
3,488
+950
+37% +$96.8K ﹤0.01% 2843
2017
Q1 		$343K Buy
2,538
+321
+14% +$47.2K ﹤0.01% 2870
2016
Q4 		$351K Buy
2,217
+884
+66% +$169K ﹤0.01% 2869
2016
Q3 		$330K Buy
1,333
+1,248
+1,468% +$457K ﹤0.01% 2932
2016
Q2 		$76K Sell
85
-21
-20% -$23.2K ﹤0.01% 3196
2016
Q1 		$96K Sell
106
-154
-59% -$151K ﹤0.01% 3220
2015
Q4 		$368K Buy
+260
New +$453K ﹤0.01% 2826

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Renaissance Technologies's ELDN Position: Q1 2026 in Review

Renaissance Technologies reduced its Eledon Pharmaceuticals (ELDN) stake by 86% in Q1 2026, selling an estimated $359K and leaving 24,600 shares worth $75.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3066.

Renaissance Technologies first reported a position in ELDN in Q4 2015 and has held it in 42 quarters since. The position peaked at $1.37M in Q2 2018. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Renaissance Technologies held 24,600 shares of Eledon Pharmaceuticals worth $75.8K as of Q1 2026.
  • Renaissance Technologies sold 152,390 Eledon Pharmaceuticals shares in Q1 2026, an estimated $359K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #3066 holding.
  • Renaissance Technologies first reported a position in Eledon Pharmaceuticals in Q4 2015 and has held it in 42 quarters since.
  • Renaissance Technologies's Eledon Pharmaceuticals position peaked at $1.37M in Q2 2018.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.